Business
EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD
Study remains on track to report top line data in Q4 2021 WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a
About this update from Eyepoint, Inc.
[{"type":"text","content":"Study remains on track to report top line data in Q4 2021\nWATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced positive safety results from its Phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD). All dose cohorts have reached at least 30-day post-dosing follow up. “We are pleased by the 30-day safety data seen for all three cohorts of the EYP-1901 DAVIO trial in patients with wet AMD,” said Nancy Lurker, CEO of EyePoint Pharmaceuticals. “These early results continue to support our belief in the potential of EYP-1901 to be a safe and effective therapeutic for long-term treatment of wet AMD. We are looking forward to releasing interim efficacy results once we have sufficient follow-up data for all dose cohorts in the fourth quarter of this year. Additionally, we continue to progress toward initiating our clinical trials of EYP-1901 for diabetic retinopathy and retinal vein occlusion.” The DAVIO clinical trial of EYP-1901 enrolled 17 wet AMD patients across three dose cohorts. Key safety observations through at least 30-Day post-dosing follow-up for all patients include: No serious adverse events (SAEs), ocular or systemic, were reportedThe three subjects in cohort 1 have been followed for a minimum of four months with no reported SAE’sTo date, there are no reported adverse events (AEs) related to significant intraocular inflammation, best-corrected visual acuity (BCVA) reduction, or elevation of intraocular pressure (IOP)No events of endophthalmitis, retinal detachment or migration into the anterior chamber have been reported to date The patients enrolled in the Phase 1 DAVIO open-label, dose escalation trial were previously treated with standard of care anti-VEGF therapies. EYP-1901 is delivered via a single intravitreal injection in the physician's office. The primary endpoint of the trial is safety, and key secondary endpoints are best corrected visual acuity (BCVA) and central subfield thickness (CST) as measured by optical coherence tomography (OCT). EYP-1901 utilizes the Company’s proprietary Durasert® drug delivery te...